Is IDXX a Buy After Dropping 26% From Its High?

IDEXX Hasn't Seen a Sell-Off This Severe in Years. Is It a Rare Entry Point?

The last 3 times IDEXX Laboratories, Inc. (IDXX) reached a drawdown severity level this extreme, it took an average of 1,799 days to fully recover to previous highs. As of April 29, 2026, the stock has officially crossed from the yellow zone into the red zone, marking a significant shift in its risk profile. This transition indicates that the current price action is no longer a standard correction but a high-severity event based on our proprietary data.

A Deep Dive Into the Current Red Zone Transition

As of April 29, 2026, IDEXX Laboratories, Inc. (IDXX) is trading at $568.30. This price represents a 25.9% decline from its all-time high of $766.68. While many growth stocks experience volatility, our data shows this specific movement has triggered a Drawdown Severity Score™ of 5.1.

This score places the stock firmly in the "Strong" red zone category. The sell-off has now persisted for 107 days, which is more than double the company's historical average drawdown duration of 46 days. When a stock exceeds its historical averages by this margin, the Drawdown Severity Score™ typically accelerates, reflecting the increased difficulty of a quick recovery.

How This Sell-Off Compares to Historical Norms

To understand the weight of a 25.9% drop, we must look at the total lifecycle of the ticker. We have tracked 258 total historical drawdown events for IDXX. Across those hundreds of events, the average maximum drawdown for the stock is only 5.1%.

The current 25.9% decline is five times more severe than the typical IDXX pullback. Our data shows that IDXX has only dropped 50% or more from its highs 3 times in its entire trading history. While the current drop has not yet reached the 50% threshold, the move into the red zone suggests the stock is entering a rare tier of historical weakness.

The Context Behind the 107-Day Slide

The market is currently processing several fundamental shifts regarding the veterinary diagnostics leader. According to Quiver Quantitative, IDEXX Laboratories recently experienced a slide as investors weighed analyst target price cuts and a significant executive reshuffle. This internal leadership change comes at a sensitive time as the company sets its 2026 strategic priorities.

Despite the price action, some analysts remain focused on the long-term fundamentals. TIKR.com recently reported that IDEXX Laboratories stock appears undervalued at the $561 level in 2026. Additionally, Seeking Alpha published a pre-earnings comparison between IDXX and Zoetis (ZTS), noting that investors are closely monitoring how IDEXX maintains its margins against its primary competitor in a tightening economy.

Analyzing the 1,799-Day Recovery Window

When examining the most severe historical drops for IDXX, the data requires a cautious interpretation. Our records show that for drops of this magnitude, the average duration of comparable events is 1,799 days. We must note a small sample size caveat here: this average is based on only 3 specific historical events.

This extended recovery timeline suggests that when IDXX breaks its standard volatility patterns, it often enters a prolonged period of consolidation or "dead money" before reclaiming its all-time highs. The Drawdown Severity Score™ of 5.1 reflects this historical tendency for deep pullbacks to require years, rather than months, to fully resolve.

Statistical Perspective on the Red Zone

The move from the yellow zone to the red zone is a quantitative signal that the asset's price behavior has deviated significantly from its 107-day trend. In the yellow zone, a stock is often in a "wait and see" period where a recovery to the mean is statistically probable. Once the Drawdown Severity Score™ hits the 5.1 level, our data indicates that the downward momentum has reached a level of historical significance.

Investors often look at these moments to determine if the asset is a "strong growth stock," as MSN recently characterized IDXX, or if the mixed share price performance reported by Simply Wall St indicates a permanent valuation rerating. Our data does not predict which outcome will occur, but it does confirm that the current 25.9% drawdown is one of the most substantial challenges the stock has faced in the modern era.

Monitoring the Path to Recovery

With the stock currently sitting at $568.30, the gap to its all-time high remains substantial. For IDXX to exit the red zone, it would need to demonstrate a sustained reversal that reduces the Drawdown Severity Score™ back toward the neutral or yellow zones. Given that the current drawdown has lasted 107 days, the stock is already well beyond its typical 46-day recovery cycle.

We will continue to track the exact numbers as IDEXX Laboratories navigates this executive reshuffle and upcoming earnings reports. The proprietary severity data remains the primary tool for distinguishing between a routine dip and a fundamental shift in investor sentiment.